Holen Sie sich die Stockscreener-App
4.10
4.59%
0.18
Handel nachbörslich:
4.40
0.30
+7.32%
Schlusskurs vom Vortag:
$3.92
Offen:
$3.95
24-Stunden-Volumen:
119.71K
Relative Volume:
2.79
Marktkapitalisierung:
$72.31M
Einnahmen:
$52.55M
Nettoeinkommen (Verlust:
$-23.69M
KGV:
-2.0297
EPS:
-2.02
Netto-Cashflow:
$-15.29M
1W Leistung:
+37.58%
1M Leistung:
+44.88%
6M Leistung:
+119.25%
1J Leistung:
+162.82%
1-Tages-Spanne:
$3.9115
$4.42
1-Wochen-Bereich:
$2.78
$4.83
52-Wochen-Spanne:
$1.3003
$4.83
Exagen Inc Stock (XGN) Company Profile
Firmenname
Exagen Inc
Sektor
Branche
Telefon
(760) 560-1501
Adresse
1261 LIBERTY WAY, VISTA, CA
Vergleichen Sie XGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| XGN | 4.10 | 72.31M | 52.55M | -23.69M | -15.29M | -2.02 |
| TMO | 513.26 | 196.32B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 235.84 | 170.34B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 133.84 | 38.48B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 201.82 | 36.63B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 417.24 | 34.17B | 3.84B | 866.24M | 792.60M | 9.80 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-05 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-04-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Eingeleitet | Cowen | Outperform |
| 2019-10-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Exagen Inc Aktie (XGN) Neueste Nachrichten
Exagen stock soars to 52-week high, hits $3.79 By Investing.com - Investing.com Canada
Exagen CEO, President & Director Acquires 7.7% More Stock - Simply Wall St
Exagen stock soars to 52-week high, hits $3.79 - Investing.com India
Exagen CFO Jeffrey Black acquires $66,448 in common stock - Investing.com India
Exagen CFO Jeffrey Black acquires $66,448 in common stock By Investing.com - Investing.com UK
Exagen president and CEO John Aballi buys $68,297 in stock By Investing.com - Investing.com Canada
Exagen president and CEO John Aballi buys $68,297 in stock - Investing.com
What is William Blair’s Forecast for Exagen FY2024 Earnings? - Defense World
Research Analysts Issue Forecasts for Exagen FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for Exagen Raised by Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Increases Earnings Estimates for Exagen - Defense World
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
William Blair Reiterates “Outperform” Rating for Exagen (NASDAQ:XGN) - Defense World
Exagen unveils new biomarkers to enhance autoimmune testing - Investing.com
Exagen Inc. Completes Validation and Regulatory Submission - GlobeNewswire
Exagen Enhances AVISE CTD Platform with 7 New Biomarkers for Autoimmune Disease Detection | XGN Stock News - StockTitan
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Exagen Inc. to Participate in Fourth Quarter Investor Conferences - The Manila Times
Exagen stock holds Sector Weight amid mixed 3Q24 results By Investing.com - Investing.com Australia
Exagen CEO to Present at Three Major Healthcare Investor Conferences | XGN Stock News - StockTitan
Exagen (NASDAQ:XGN) Receives Outperform Rating from William Blair - MarketBeat
Exagen Inc. (NASDAQ:XGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Ch - GuruFocus.com
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... - Yahoo Finance
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... By GuruFocus - Investing.com Canada
Exagen Inc. Reports Q3 2024 Financial Results - TipRanks
Exagen Inc. (XGN) Quarterly 10-Q Report - Quartzy
Exagen stock holds Sector Weight amid mixed 3Q24 results - Investing.com
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates - MSN
Exagen Inc (XGN) Q3 2024 Earnings: Revenue Misses Estimates at $12.5M, Net Loss Narrows to $5.0M - GuruFocus.com
Exagen Inc. Reports Third Quarter 2024 Results - GlobeNewswire
Exagen Q3 Revenue Hits $12.5M Despite Setbacks; YTD Performance Shows 37% Loss Reduction | XGN Stock News - StockTitan
Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect - GuruFocus.com
Exagen (XGN) to Release Earnings on Tuesday - Defense World
Exagen to Announce Third Quarter 2024 Results on November 12, 2024 - GlobeNewswire
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence - The Manila Times
Renaissance Technologies LLC Boosts Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Exagen Insider Stock Sales Prove Timely As Market Valuation Descends To US$47m - Simply Wall St
Stonepine Capital Management LLC Has $653,000 Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Exagen Inc. (NASDAQ:XGN) Shares Sold by Nantahala Capital Management LLC - Defense World
Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges - Investing.com
Exagen Inc. (NASDAQ:XGN) Short Interest Up 20.9% in September - MarketBeat
Octopus Energy acquires solar and storage company Exagen Group - Yahoo Finance
Octopus buys British solar and battery storage firm Exagen - Reuters
PARP Inhibitor Biomarkers Market Expected to Reach $1.75 Billion by 2031 - WhaTech
Autoimmune Disease Diagnostics Market 2024 Global Insights and Business Scenario 2031 - Newstrail
San Diego 2024 Top Tech Awards ceremony set for Sept. 26 at Snapdragon Stadium - CBS News 8
Autoimmune Disease Testing Market to Reach $12.1 Billion, Globally, by 2033 at 8.6% CAGR: Allied Market Research - PR Newswire UK
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now - MSN
Shareholders in Exagen (NASDAQ:XGN) have lost 84%, as stock drops 12% this past week - Yahoo Finance
Finanzdaten der Exagen Inc-Aktie (XGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):